Marquette Asset Management LLC Cuts Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Marquette Asset Management LLC lessened its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 11.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 200 shares of the medical research company’s stock after selling 25 shares during the quarter. Marquette Asset Management LLC’s holdings in Thermo Fisher Scientific were worth $106,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also modified their holdings of TMO. Golden State Equity Partners purchased a new stake in Thermo Fisher Scientific during the fourth quarter worth about $346,000. Sonen Capital LLC grew its holdings in shares of Thermo Fisher Scientific by 9.0% in the 4th quarter. Sonen Capital LLC now owns 1,963 shares of the medical research company’s stock worth $1,042,000 after acquiring an additional 162 shares during the period. Mountain Pacific Investment Advisers Inc. ID increased its stake in Thermo Fisher Scientific by 1.5% in the 4th quarter. Mountain Pacific Investment Advisers Inc. ID now owns 41,671 shares of the medical research company’s stock valued at $22,118,000 after purchasing an additional 620 shares in the last quarter. Markel Group Inc. boosted its position in Thermo Fisher Scientific by 44.1% during the fourth quarter. Markel Group Inc. now owns 19,600 shares of the medical research company’s stock worth $10,403,000 after purchasing an additional 6,000 shares in the last quarter. Finally, K.J. Harrison & Partners Inc acquired a new stake in Thermo Fisher Scientific in the fourth quarter valued at $2,748,000. 89.23% of the stock is owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Trading Up 0.3 %

NYSE:TMO traded up $1.87 during trading hours on Friday, reaching $573.60. 1,438,184 shares of the company were exchanged, compared to its average volume of 1,317,052. Thermo Fisher Scientific Inc. has a 52-week low of $415.60 and a 52-week high of $603.82. The stock has a 50 day simple moving average of $573.60 and a 200 day simple moving average of $530.14. The firm has a market cap of $218.95 billion, a price-to-earnings ratio of 36.79, a PEG ratio of 2.42 and a beta of 0.80. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.70 and a quick ratio of 1.39.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings results on Wednesday, April 24th. The medical research company reported $5.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.70 by $0.41. The firm had revenue of $10.35 billion during the quarter, compared to the consensus estimate of $10.14 billion. Thermo Fisher Scientific had a return on equity of 18.45% and a net margin of 14.20%. As a group, analysts predict that Thermo Fisher Scientific Inc. will post 21.56 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, April 15th. Shareholders of record on Friday, March 15th were given a dividend of $0.39 per share. This represents a $1.56 dividend on an annualized basis and a yield of 0.27%. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. The ex-dividend date was Thursday, March 14th. Thermo Fisher Scientific’s payout ratio is 10.01%.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 14,566 shares of the firm’s stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total value of $8,186,092.00. Following the transaction, the senior vice president now directly owns 12,901 shares of the company’s stock, valued at $7,250,362. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 14,566 shares of the company’s stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total value of $8,186,092.00. Following the completion of the transaction, the senior vice president now owns 12,901 shares in the company, valued at approximately $7,250,362. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Debora L. Spar sold 164 shares of the business’s stock in a transaction on Monday, February 12th. The stock was sold at an average price of $546.97, for a total transaction of $89,703.08. Following the transaction, the director now directly owns 1,207 shares in the company, valued at $660,192.79. The disclosure for this sale can be found here. Insiders sold 50,277 shares of company stock valued at $28,513,384 over the last 90 days. Corporate insiders own 0.32% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently commented on TMO shares. Robert W. Baird decreased their price objective on shares of Thermo Fisher Scientific from $621.00 to $620.00 and set an “outperform” rating on the stock in a research report on Thursday. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Thermo Fisher Scientific in a report on Monday, January 8th. JPMorgan Chase & Co. lifted their price objective on Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an “overweight” rating in a research report on Thursday. Citigroup initiated coverage on Thermo Fisher Scientific in a report on Monday, March 18th. They set a “neutral” rating and a $620.00 target price on the stock. Finally, Barclays boosted their price target on Thermo Fisher Scientific from $590.00 to $615.00 and gave the stock an “equal weight” rating in a report on Thursday. Five investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to data from MarketBeat.com, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and an average target price of $606.76.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.